VEGFR1, VEGFR2, KIT, MET, FLT3, RET (Group of Receptor Tyrosine Kinases) (VEGFR1, VEGFR2, KIT, MET, FLT3, RET)

Vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), KIT proto-oncogene receptor tyrosine kinase (KIT), MET proto-oncogene receptor tyrosine kinase (MET), Fms-related tyrosine kinase 3 (FLT3), and Ret proto-oncogene receptor tyrosine kinase (RET) are members of the receptor tyrosine kinase family involved in cellular signaling cascades that regulate angiogenesis, cell proliferation, survival, migration, and differentiation. These receptors play central roles in cancer pathogenesis as well as in normal developmental and physiological processes. They are therapeutic targets of several multi-kinase inhibitors, used to treat various solid tumors and some hematological malignancies, by blocking their kinase activity and consequently shutting down downstream signaling pathways essential for tumor growth and progression[1][2][3][4][5][6][7].

Other names

FLT1FLT-1Fms-like tyrosine kinase 1Vascular endothelial growth factor receptor 1KDRFLK-1Vascular endothelial growth factor receptor 2c-KitCD117Stem cell factor receptorc-MetHepatocyte growth factor receptorHGFRFms-related tyrosine kinase 3CD135Rearranged during transfectionRET proto-oncogene

Inhibition of receptor tyrosine kinase enzymatic (ATP-binding) activity, blocking phosphorylation and downstream signal transduction. Inhibition of angiogenesis (by targeting VEGFRs). Inhibition of cell proliferation, induction of apoptosis (KIT, FLT3, MET, RET, etc.). Inhibition of tumor migration, invasiveness, and metastatic spread.